These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34911880)

  • 1. Tubular Injury Causing Protracted Glycosuria Following Withdrawal of a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor: A Possible Role in the Development of Protracted Hypoglycemia and Ketoacidosis.
    Hashi R; Fujiki N; Yagi T
    Tohoku J Exp Med; 2021 Dec; 255(4):291-296. PubMed ID: 34911880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atypical Ketoacidosis and Protracted Hyperglycosuria after Treatment with Ipragliflozin, an SGLT2 Inhibitor.
    Miyauchi M; Toyoda M; Fukagawa M
    Intern Med; 2017; 56(13):1673-1678. PubMed ID: 28674356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ketoacidosis with euglycemia in a patient with type 2 diabetes mellitus taking dapagliflozin: A case report.
    Yeo SM; Park H; Paek JH; Park WY; Han S; Park SB; Jin K
    Medicine (Baltimore); 2019 Jan; 98(3):e14150. PubMed ID: 30653152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Euglycemic Diabetic Ketoacidosis with Elevated Acetone in a Patient Taking a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor.
    Andrews TJ; Cox RD; Parker C; Kolb J
    J Emerg Med; 2017 Feb; 52(2):223-226. PubMed ID: 27717592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives.
    Qiu H; Novikov A; Vallon V
    Diabetes Metab Res Rev; 2017 Jul; 33(5):. PubMed ID: 28099783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
    Burke KR; Schumacher CA; Harpe SE
    Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Euglycemic ketoacidosis : a complication of SGLT2 inhibitors].
    Mizuno A; Lolachi S; Pernet A
    Rev Med Suisse; 2017 May; 13(565):1164-1167. PubMed ID: 28639760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Life-threatening ketoacidosis in a 25-year-old woman treated with sodium-glucose cotransporter 2 inhibitor].
    Lindberg MJ; Kristensen FB; Yildiz A
    Ugeskr Laeger; 2016 Nov; 178(47):. PubMed ID: 27908315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Euglycemic ketosis in patients with type 2 diabetes on SGLT2-inhibitor therapy-an emerging problem and solutions offered by diabetes technology.
    Pfützner A; Klonoff D; Heinemann L; Ejskjaer N; Pickup J
    Endocrine; 2017 Apr; 56(1):212-216. PubMed ID: 28303514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGLT2 Inhibitors May Predispose to Ketoacidosis.
    Taylor SI; Blau JE; Rother KI
    J Clin Endocrinol Metab; 2015 Aug; 100(8):2849-52. PubMed ID: 26086329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes.
    Herring RA; Shojaee-Moradie F; Garesse R; Stevenage M; Jackson N; Fielding BA; Mendis A; Johnsen S; Umpleby AM; Davies M; Russell-Jones DL
    Diabetes Care; 2020 Sep; 43(9):2128-2136. PubMed ID: 32641376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicentre prospective observational study of sodium-glucose cotransporter-2 inhibitor-associated postoperative ketoacidosis: the SAPKA study protocol.
    Seki H; Kuratani N; Shiga T; Iwasaki Y; Karita K; Yasuda K; Yorozu T
    BMJ Open; 2021 Nov; 11(11):e049592. PubMed ID: 34815277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Acidosis without marked hyperglycemia : Euglycemic diabetic ketoacidosis associated with SGLT2-Inhibitors].
    Valek R; Von der Mark J
    Med Klin Intensivmed Notfmed; 2017 Mar; 112(2):145-148. PubMed ID: 27221094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SGLT2-inhibitors: a novel class for the treatment of type 2 diabetes introduction of SGLT2-inhibitors in clinical practice.
    Cuypers J; Mathieu C; Benhalima K
    Acta Clin Belg; 2013; 68(4):287-93. PubMed ID: 24455799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Euglycemic diabetic ketoacidosis induced by sodium-glucose cotransporter 2 inhibitor in the setting of prolonged fasting: a case report.
    Alkatheeri A; Alseddeeqi E
    J Med Case Rep; 2022 Mar; 16(1):138. PubMed ID: 35346357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-glucose co-transporter-2 inhibitor-associated euglycemic diabetic ketoacidosis that prompted the diagnosis of fulminant type-1 diabetes: A case report.
    Yasuma T; Okano Y; Tanaka S; Nishihama K; Eguchi K; Inoue C; Maki K; Uchida A; Uemura M; Suzuki T; D'Alessandro-Gabazza CN; Gabazza EC; Yano Y
    World J Clin Cases; 2021 May; 9(13):3163-3169. PubMed ID: 33969104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus.
    Hohendorff J; Szopa M; Skupien J; Kapusta M; Zapala B; Platek T; Mrozinska S; Parpan T; Glodzik W; Ludwig-Galezowska A; Kiec-Wilk B; Klupa T; Malecki MT
    Endocrine; 2017 Aug; 57(2):272-279. PubMed ID: 28593615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Euglycemic Ketoacidosis in a Patient without Diabetes Taking Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure.
    Miyazaki M; Nakano M; Takahashi H; Isaka Y; Hiura Y
    Am J Case Rep; 2024 Jul; 25():e943945. PubMed ID: 38985686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Euglycemic Diabetic Ketoacidosis Caused by a Sodium-glucose Co-transporter (SGLT) 2 Inhibitor after Coronary Artery Bypass Grafting].
    Kameda Y; Kato M; Inoue B; Yamazaki S; Sahara N; Aoki T; Nagashima Y; Nemoto N; Anzai H; Araki W; Kobayashi N
    Kyobu Geka; 2019 May; 72(5):354-357. PubMed ID: 31268032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemodynamic and renal implications of sodium-glucose cotransporter- 2 inhibitors in type 2 diabetes mellitus.
    Tejedor Jorge A
    Med Clin (Barc); 2016 Nov; 147 Suppl 1():35-43. PubMed ID: 28760224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.